This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome
by Zacks Equity Research
Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.
Exact Sciences (EXAS) Gains From New Buyouts Amid High Costs
by Zacks Equity Research
Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is now offering therapy selection tests for patients with advanced cancer.
Thermo Fisher (TMO) Gets FDA Clearance for Its Immunoassays
by Zacks Equity Research
Thermo Fisher (TMO) announces the FDA clearance of its blood-based biomarkers used in the determination of risk assessment and clinical management of preeclampsia with severe features.
Illumina (ILMN) Progresses in Pathogen Genomic Technologies
by Zacks Equity Research
Illumina's (ILMN) genomic surveillance solutions enable better pathogen preparedness and response.
Hologic (HOLX) Announces Collaboration With NFL CB Kelee Ringo
by Zacks Equity Research
Hologic (HOLX) and Eagles' CB, Kelee Ringo, come together to highlight the importance of annual mammograms and other routine health screenings.
Integra (IART) Builds Advanced R&D Facility in New Jersey
by Zacks Equity Research
Integra (IART) opens the Dr. Richard E. Caruso Center of Innovation and Learning in New Jersey.
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 2.56% and 2.85%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 30.23% and 9.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
5 Winning Medical Product Stocks That Still Have Room to Run
by Indrajit Bandyopadhyay
Despite ongoing macro challenges, medical product stocks like Cardinal Health (CAH), TransMedics Group (TMDX), Olink Holding (OLK), Silk Road Medical (SILK) and Neuronetics (STIM) are likely to gain from strong fundamentals.
Is Neuronetics (STIM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Neuronetics (STIM) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.
Neuronetics (STIM) Is Up 12.75% in One Week: What You Should Know
by Zacks Equity Research
Does Neuronetics (STIM) have what it takes to be a top stock pick for momentum investors? Let's find out.
New Strong Buy Stocks for November 16th
by Zacks Equity Research
ENTX, STIM, FN, ANGN and FUTU have been added to the Zacks Rank #1 (Strong Buy) List on November 16, 2022.
Neuronetics (STIM) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 36.36% and 11.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Penumbra (PEN) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 200% and 0.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of 15.09% and 4.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of 16.67% and 2.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics (STIM) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 9.30% and 6.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint Neuro, Inc. (CLPT) Surges 7.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 0% and 7.43%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Stereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of 0% and 0.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Treace Medical Concepts (TMCI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of 20% and 10.95%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of 26.92% and 11.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Apollo Endosurgery, Inc. (APEN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apollo Endosurgery, Inc. (APEN) delivered earnings and revenue surprises of 0% and 6.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Community Health (CYH) Stock
by Zacks Equity Research
With contract labor headwinds likely to phase out as 2022 progresses, Community Health Systems' (CYH) margins are set to improve significantly.